Stromal alterations in patients with MGUS, smoldering myeloma and multiple myeloma

Lucienne Bogun,Annemarie Koch,Bo Scherer,Roland Fenk,Uwe Maus,Felix Bormann,Karl Köhrer,Patrick Petzsch,Thorsten Wachtmeister,Romans Zukovs,Sascha Dietrich,Rainer Haas,Thomas Schroeder,Paul Sebastian Jäger,Stefanie Geyh
DOI: https://doi.org/10.1182/bloodadvances.2023011632
IF: 7.642
2024-01-19
Blood Advances
Abstract:The hallmark of multiple myeloma (MM) is a clonal plasma cell infiltration in the bone marrow accompanied by myelosuppression and osteolysis. Premalignant stages like monoclonal gammopathy of undetermined significance (MGUS) and asymptomatic stages like smoldering myeloma (SMM) can progress to multiple myeloma (MM). Mesenchymal stromal cells (MSC) are an integral component of the bone marrow microenvironment and play an important role for osteoblast differentiation and hematopoietic support. While stromal alterations have been reported in MM contributing to hematopoietic insufficiency and osteolysis, it is not clear whether alterations in MSC already occur in MGUS or SMM. In this study we analyzed MSC from MGUS, SMM and MM towards their properties and functionality and performed mRNA sequencing to find underlying molecular signatures in different disease stages. A high number of senescent cells and a reduced osteogenic differentiation capacity and hematopoietic support was already present in MGUS MSC. As shown by RNA sequencing there was a broad spectrum of differentially expressed genes including genes of the BMP/TGF-signaling pathway, detected already in MGUS and that clearly increases in SMM and MM patients. Our data may help to block these signaling pathways in the future to hinder progression to multiple myeloma.
hematology
What problem does this paper attempt to address?